Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | — | — | — | — | — | $0.00 | $0.00 | $1.00M | $170K |
| Revenue growth | — | — | — | — | — | — | — | — | — | -83.0% |
| Operating income | -$29.5M | -$27.6M | -$17.0M | -$20.1M | -$19.1M | -$29.1M | -$57.6M | -$25.7M | -$22.4M | -$18.2M |
| Operating margin | -83.6% | — | — | — | — | — | — | — | -2240.9% | -10711.2% |
| Net income | -$32.7M | $23.0M | -$16.2M | -$19.4M | -$8.15M | -$27.5M | -$54.2M | -$20.8M | -$20.0M | -$16.6M |
| Net margin | -92.6% | — | — | — | — | — | — | — | -1998.5% | -9756.5% |
| EPS (diluted) | -$4.99 | $2.56 | -$1.67 | -$1.88 | -$0.53 | -$7.45 | -$10.47 | -$2.58 | -$2.40 | -$1.91 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.7M | -$20.9M | -$20.0M | -$18.9M | -$8.82M | -$22.2M | -$21.2M | -$20.0M | -$19.4M | -$15.9M |
| Capital expenditures | $1.10M | $135K | $134K | $0.00 | $20.0K | $60.0K | $285K | $0.00 | $0.00 | $28.0K |
| Free cash flow | -$24.8M | -$21.0M | -$20.1M | -$18.9M | -$8.84M | -$22.3M | -$21.5M | -$20.0M | -$19.4M | -$16.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.08M | $29.2M | $10.3M | $14.0M | $16.5M | $24.6M | $32.2M | $22.6M | $16.2M | $16.0M |
| Total assets | $53.5M | $63.4M | $44.6M | $27.2M | $36.0M | $97.0M | $73.0M | $54.7M | $35.0M | $17.7M |
| Total liabilities | $30.0M | $13.2M | $7.13M | $6.60M | $3.76M | $5.01M | $6.71M | $6.80M | $5.68M | $3.14M |
| Long-term debt | $2.52M | $0.00 | — | — | — | — | — | — | — | — |
| Shareholders' equity | $4.88M | $50.5M | $37.7M | $20.8M | $32.5M | $92.3M | $66.6M | $48.1M | $29.6M | $14.9M |
| Retained earnings | -$405M | -$382M | -$398M | -$417M | -$426M | -$453M | -$507M | -$528M | -$548M | -$565M |
| Shares (wtd avg diluted) | 6.55M | 8.97M | 9.69M | 10.5M | 15.4M | 3.69M | 5.18M | 8.07M | 8.33M | 8.69M |
Every figure is extracted from LISATA THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.